{"name":"Gi-Byoung Nam","slug":"gi-byoung-nam","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Edoxaban plus Single Antiplatelet Agent","genericName":"Edoxaban plus Single Antiplatelet Agent","slug":"edoxaban-plus-single-antiplatelet-agent","indication":"Acute coronary syndrome (with single antiplatelet agent)","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Edoxaban Monotherapy","genericName":"Edoxaban Monotherapy","slug":"edoxaban-monotherapy","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Edoxaban plus Single Antiplatelet Agent","genericName":"Edoxaban plus Single Antiplatelet Agent","slug":"edoxaban-plus-single-antiplatelet-agent","phase":"marketed","mechanism":"Edoxaban inhibits Factor Xa to prevent blood clot formation, while a single antiplatelet agent (such as aspirin or clopidogrel) blocks platelet aggregation, providing dual antithrombotic protection.","indications":["Acute coronary syndrome (with single antiplatelet agent)","Stroke prevention in atrial fibrillation (with single antiplatelet agent in select patients)"],"catalyst":""},{"name":"Edoxaban Monotherapy","genericName":"Edoxaban Monotherapy","slug":"edoxaban-monotherapy","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE9sRW5CTG5WN01aS2xiZFphVkZKbU5HSHpyb2plaE5jMnhXbHZnVGhpNktxMzZRYkNHU2p3U1lNUXZJNno3a0x5LTFxc3VWLVhjSHRFbXVsZWFST09GcVFNZQ?oc=5","date":"2026-03-04","type":"trial","source":"JACC Journals","summary":"Anticoagulation Alone or With Antiaggregation in Patients With Coronary Artery Disease: Meta-Analysis of Randomized Trials - JACC Journals","headline":"Anticoagulation Alone or With Antiaggregation in Patients With Coronary Artery Disease: Meta-Analysis of Randomized Tria","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE9JS2xFaXBRVndLOHBBc25kM3VRaVRxZjhkQWpKUi1wa2YtZFVIR216ZE1LVXVBZGw0THlacVoyYzhCd1FMZHAtRkxFNmlkWTY1d09UWFZKUGZpNnZPb3F4enRjXzNnM2VwcUE?oc=5","date":"2025-03-27","type":"pipeline","source":"Wiley Online Library","summary":"Comparison of Clinical Outcomes Between Left Bundle Branch Area Pacing With a Stylet-Driven Lead and Conventional Right Ventricular Pacing - Wiley Online Library","headline":"Comparison of Clinical Outcomes Between Left Bundle Branch Area Pacing With a Stylet-Driven Lead and Conventional Right ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNU2EwZGVjaUQ1Y0VndlRMeTl6QlExTU9JWXNwYmZXa3FsVVJfM1BCNVFNMHZMamVXRTZ2Y2tBNXZrVnQ1RlloM2F1VFV0aVhIVlB0MjBTYng3SHBuNjZSaG5fMzJHQXk5dU40OXcxUW4tazVLWlBxSlVHVnMtejk4T1M1M2Z4cVlic1RmX2xmdE82RnZjVkxN?oc=5","date":"2024-09-01","type":"pipeline","source":"TCTMD.com","summary":"Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD - TCTMD.com","headline":"Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTFB1U2U2b25MbVlzWWZtb2xmRXdIMVhBRVF3MFZFTERIQk1wbnEwaU5Yb2xjaDZHcXNZeWRCakItVWFhQUk5anNHam5RV3E1Y21zTnF6OVl0RDZjRXpnSFVPTUJkakxHSFJwOEZKRw?oc=5","date":"2018-12-03","type":"trial","source":"American Heart Association Journals","summary":"Outcomes After Use of Standard- and Low-Dose Non–Vitamin K Oral Anticoagulants in Asian Patients With Atrial Fibrillation - American Heart Association Journals","headline":"Outcomes After Use of Standard- and Low-Dose Non–Vitamin K Oral Anticoagulants in Asian Patients With Atrial Fibrillatio","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}